Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

Background:There are contradictory reports regarding the effects of protease inhibitors on the ECG measures of QT and PR interval durations. The effect of interrupting use of protease inhibitors on QT and PR progression is also unknown. Methods:This analysis included 3719 participants from the Strategies for Management of Antiretroviral Therapy (SMART) study, of whom 1879 were randomized to receive intermittent antiretroviral therapy (ART) (drug conservation group), whereas the rest received these drugs continuously (viral suppression group). Linear regression analysis was used to compare four ritonavir-boosted protease inhibitor (protease inhibitor/r) regimens [saquinavir (SQV/r), lopinavir (LPV/r), atazanavir (ATV/r), and other protease inhibitor/r], and nonboosted protease inhibitor regimens with nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens for Bazett's (QTcB) and Fredericia's (QTcF) heart rate corrected QT and PR. Changes in QTcB, QTcF, and PR after 12 and 24 months of randomization were compared in the drug conservation group and viral suppression group. Results:Average levels of QTcB, QTcF, and PR duration at entry were 415, 406, and 158 ms. At study entry, 49% of participants were taking an NNRTI (no protease inhibitor)-based regimen and 31% were prescribed a boosted protease inhibitor, the most common being LPV/r. After adjustment for baseline factors, QTcB and QTcF levels did not vary by boosted protease inhibitor group (P = 0.26 and P = 0.34, respectively). For those given any of the boosted protease inhibitors, QTcB was 1.5 ms lower than the NNRTI group (P = 0.04). Both boosted and nonboosted protease inhibitor-containing regimens were significantly associated (P < 0.01 for each) with longer PR intervals compared to the NNRTI group. After adjustment, the difference between boosted protease inhibitors and the NNRTI group was 5.11 ms (P < 0.01); for nonboosted protease inhibitors, this difference was 3.00 ms (P < 0.01). Following ART interruption, PR duration declined for both the boosted and nonboosted protease inhibitor groups and compared to the viral suppression group, significant changes in PR interval were observed 24 months after ART interruption of boosted protease inhibitors (P < 0.01). Conclusion:Different protease inhibitor-based regimens have a similar, minimal effect on QT compared to NNRTI-based regimens. All protease inhibitor-based regimens (boosted and nonboosted) were associated with prolongation of PR, and interruption of protease inhibitor regimens reduced the prolonged PR duration. Further research is needed to confirm the findings of this study and assess the clinical relevance of the differences.

[1]  MattDewhurst,et al.  Regarding Article “Ethnic Distribution of Electrocardiographic Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities Study (ARIC)” , 2011 .

[2]  R. Arora,et al.  HIV Protease Inhibitors Induced Prolongation of the QT Interval: Electrophysiology and Clinical Implications , 2010, American journal of therapeutics.

[3]  M. Gold,et al.  Long-term Outcomes in Individuals With Prolonged PR Interval or First-Degree Atrioventricular Block , 2010 .

[4]  E. Acosta,et al.  Electrocardiogram Abnormalities with Atazanavir and Lopinavir/Ritonavir , 2009, HIV clinical trials.

[5]  L. S. Fridericia.  Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken , 2009 .

[6]  Zhu-ming Zhang,et al.  Ethnic Distribution of ECG Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities (ARIC) Study , 2009, Stroke.

[7]  D. Levy,et al.  Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study , 2009, The Lancet.

[8]  P. Boelle,et al.  Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. , 2009, British journal of clinical pharmacology.

[9]  A. Phillips,et al.  Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. , 2008, Annals of internal medicine.

[10]  C. Angeletti,et al.  Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. , 2007, The Journal of infection.

[11]  M. Ruiz,et al.  Prolonged QT interval and torsades de pointes associated with atazanavir therapy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  P. Rautaharju,et al.  Investigative Electrocardiography in Epidemiological Studies and Clinical Trials , 2007 .

[13]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[14]  R. Woosley,et al.  Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. , 2006, Heart rhythm.

[15]  AJ Busti,et al.  A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patients , 2006, HIV medicine.

[16]  Makoto Ito,et al.  Arrhythmogenesis in the short-QT syndrome associated with combined HERG channel gating defects: a simulation study. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[17]  J. Hsia,et al.  Normal standards for QT and QT subintervals derived from a large ethnically diverse population of women aged 50 to 79 years (the Women's Health Initiative [WHI]). , 2006, The American journal of cardiology.

[18]  Michael J Ackerman,et al.  Blockade of HERG channels by HIV protease inhibitors , 2005, The Lancet.

[19]  J. Mor,et al.  Prevalence and risk factors for prolonged QTc in a multiethnic cohort in rural Hawaii. , 2005, Clinical biochemistry.

[20]  Peter W Macfarlane,et al.  A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. , 2004, Journal of electrocardiology.

[21]  J. Brugada,et al.  Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.

[22]  R. Zeldin,et al.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.

[23]  John W. Mellors,et al.  Panel on Clinical Practices for Treatment of HIV Infection , 2000 .

[24]  George Howard,et al.  High‐resolution B‐Mode Ultrasound Scanning Methods in the Atherosclerosis Risk in Communities Study (ARIC) , 1991, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[25]  P. Rautaharju,et al.  Estimation of QT prolongation. A persistent, avoidable error in computer electrocardiography. , 1990, Journal of electrocardiology.

[26]  S. Carruthers,et al.  Relationships between heart rate and PR interval during physiological and pharmacological interventions. , 1987, British journal of clinical pharmacology.

[27]  T. Chou.  Electrocardiography In Clinical Practice , 1979 .

[28]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .